


Highlights of This Issue 1335

COMMENTARY

- 1337** Stem Cell Factor LIFted as a Promising Clinical Target for Cancer Therapy
Yu Shi, Sean Hunter, and Tony Hunter
See related article, p. 1341

SMALL MOLECULE THERAPEUTICS

- 1341** EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer
Suryavathi Viswanadhappalli, Yiliao Luo, Gangadhara R. Sareddy, Bindu Santhamma, Mei Zhou, Mengxing Li, Shihong Ma, Rajni Sonavane, Uday P. Pratap, Kristin A. Altwegg, Xiaonan Li, Annabel Chang, Alejandra Chávez-Riveros, Kalarickal V. Dileep, Kam Y.J. Zhang, Xinlei Pan, Ramachandran Murali, Marek Bajda, Ganesh V. Raj, Andrew J. Brenner, Vijaya Manthathi, Manjeet K. Rao, Rajeshwar R. Tekmal, Hareesh B. Nair, Klaus J. Nickisch, and Ratna K. Vadlamudi
See related commentary p. 1337
- 1355** Combinatorial Therapy of Zinc Metallochaperones with Mutant p53 Reactivation and Diminished Copper Binding
Saif Zaman, Xin Yu, Anthony F. Bencivenga, Adam R. Blanden, Yue Liu, Tracy Withers, Bing Na, Alan J. Blayney, John Gilleran, David A. Boothman, Stewart N. Loh, S. David Kimball, and Darren R. Carpizo
- 1366** Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression
Hiroaki Tanaka, Hideki Sakagami, Naoki Kaneko, Satoshi Konagai, Hiroko Yamamoto, Takahiro Matsuya, Masatoshi Yuri, Yosuke Yamanaka, Masamichi Mori, Masahiro Takeuchi, Hiroyuki Koshio, Masaaki Hirano, and Sadao Kuromitsu
- 1374** Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition
 Gary K. Scott, Christina Yau, Beatrice C. Becker, Sana Khateeb, Sophia Mahoney, Martin Borch Jensen, Byron Hann, Bryan J. Cowen, Scott D. Pegan, and Christopher C. Benz

LARGE MOLECULE THERAPEUTICS

- 1386** A Short SOX9 Peptide Mimics SOX9 Tumor Suppressor Activity and Is Sufficient to Inhibit Colon Cancer Cell Growth
Philippe Blache, Lucile Canterel-Thouennon, Muriel Busson, Pascal Verdié, Gilles Subra, Marc Ychou, and Corinne Prévostel

CANCER BIOLOGY AND TRANSLATIONAL STUDIES


- 1396** Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers
 Adam Stewart, Elizabeth A. Coker, Sebastian Pölsterl, Alexandros Georgiou, Anna R. Minchom, Suzanne Carreira, David Cunningham, Mary ER. O'Brien, Florence I. Raynaud, Johann S. de Bono, Bissan Al-Lazikani, and Udai Banerji
- 1405** Vorinostat Potentiates 5-Fluorouracil/Cisplatin Combination by Inhibiting Chemotherapy-Induced EGFR Nuclear Translocation and Increasing Cisplatin Uptake
Geny Piro, Maria Serena Roca, Francesca Bruzzese, Carmine Carbone, Federica Iannelli, Alessandra Leone, Maria Grazia Volpe, Alfredo Budillon, and Elena Di Gennaro
- 1418** Oncolytic Herpes Virus Armed with Vasculostatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways
Yusuke Tomita, Kazuhiko Kurozumi, Ji Young Yoo, Kentaro Fujii, Tomotsugu Ichikawa, Yuji Matsumoto, Atsuhito Uneda, Yasuhiko Hattori, Toshihiko Shimizu, Yoshihiro Otani, Tetsuo Oka, Balveen Kaur, and Isao Date
- 1430** Sentinel Lymph Node-Targeted Therapy by Oncolytic Sendai Virus Suppresses Micrometastasis of Head and Neck Squamous Cell Carcinoma in an Orthotopic Nude Mouse Model
Yuya Tanaka, Koji Araki, Shingo Tanaka, Yoshihiro Miyagawa, Hiroshi Suzuki, Daisuke Kamide, Masayuki Tomifuji, Kosuke Uno, Eiko Kimura, Taku Yamashita, Yasuji Ueda, and Akihiro Shiotani
- 1439** The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer
Yuping Yin, Weizhen Liu, Qian Shen, Peng Zhang, Lulu Wang, Ruikang Tao, Hang Li, Xianxiong Ma, Xiangyu Zeng, Jae-Ho Cheong, Shumei Song, Jaffer A. Ajani, Gordon B. Mills, Kaixiong Tao, and Guang Peng


Table of Contents

COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

- 1451** Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia
Dimitrios Papaioannou, Deedra Nicolet, Hatice G. Ozer, Krzysztof Mrózek, Stefano Volinia, Paolo Fadda, Andrew J. Carroll, Jessica Kohlschmidt, Jonathan E. Koltitz, Eunice S. Wang, Richard M. Stone, John C. Byrd, Ramiro Garzon, and Clara D. Bloomfield


MODELS AND TECHNOLOGIES

- 1460** Identifying Candidate Druggable Targets in Canine Cancer Cell Lines Using Whole-Exome Sequencing
Sunetra Das, Rupa Idate, Kathryn E. Cronise, Daniel L. Gustafson, and Dawn L. Duval

 AC icon indicates AuthorChoice
For more information please visit www.aacrjournals.org

ABOUT THE COVER

The treatment of N0 head and neck squamous cell carcinoma remains controversial between dissecting the neck or watchfully monitoring the condition. To generate a new option, Dr. Tanaka and colleagues developed a urokinase-type plasminogen activator-dependent oncolytic Sendai virus ("Bioknife"). In the cover image, GFP-expressing Bioknife is shown to be present in the tongue after injection into an orthotopic xenograft in mice. The authors further demonstrate Bioknife migrates to the sentinel lymph node where it suppressed lymph node metastasis. Read the full article on page 1430.



Molecular Cancer Therapeutics

18 (8)

Mol Cancer Ther 2019;18:1335-1471.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/18/8>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/18/8>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.